Skip to content

Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06848530
Enrollment
100
Registered
2025-02-27
Start date
2025-12-10
Completion date
2030-04-01
Last updated
2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Movement Disorders

Brief summary

The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and/or through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.

Interventions

OTHERPrescribed Medications

participant's movement disorders medications, prescribed by their treating physician

OTHERDeep brain stimulation adjustment

Deep brain stimulator parameters may be adjusted within normal clinical limits

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 18 years of age and above * Any patient who has been diagnosed by a movement disorders neurologist with one of the following movement disorders: * Parkinson's disease * Dystonia * Tremor, including essential tremor * Cerebellar ataxia * Other hyperkinetic movement disorders, such as chorea and tics

Exclusion criteria

\- Patients with dementia

Design outcomes

Primary

MeasureTime frameDescription
Neural signal biomarkers5 yearsSpatiotemporal patterns of brain neural activity (neural signal biomarkers / neurophysiologic signatures) associated with movement disorders symptoms.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026